{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=17&q=follicular+lymphoma", "query": { "q": "follicular lymphoma", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 172, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=18&q=follicular+lymphoma&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=16&q=follicular+lymphoma&page_size=10" }, "source": "local", "last_synced_at": "2026-10-16T01:55:47.738Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05410418", "title": "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Lymphoma, Follicular" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2022-10-24", "completion_date": "2029-04-24", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-04-20T11:28:38.507Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05410418" }, { "nct_id": "NCT05565417", "title": "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Burkitt Lymphoma", "Colorectal Cancer", "Cutaneous Squamous Cell Carcinoma", "Diffuse Large B Cell Lymphoma", "Esophageal Cancer", "Follicular Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Hodgkin Lymphoma", "Hormone Receptor Positive Breast Carcinoma", "Non Small Cell Lung Cancer", "Small Bowel Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Fruquintinib", "type": "COMBINATION_PRODUCT" }, { "name": "IMT-009", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Immunitas Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2022-11-28", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-01T00:07:31.912Z", "location_count": 9, "location_summary": "Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05565417" }, { "nct_id": "NCT05371093", "title": "Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2022-09-22", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-10-14T12:10:05.946Z", "location_count": 12, "location_summary": "Duarte, California • Stanford, California • Tampa, Florida + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05371093" }, { "nct_id": "NCT03147885", "title": "Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Extranodal Marginal Zone Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Indolent Adult Non-Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Extranodal Marginal Zone Lymphoma", "Refractory Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Stage III Non-Hodgkin Lymphoma", "Stage IV Non-Hodgkin Lymphoma", "Transformed Recurrent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-06-20", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-10-15T07:16:11.445Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03147885" }, { "nct_id": "NCT03150329", "title": "Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Grade 3b Follicular Lymphoma", "Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL", "Recurrent Classic Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL", "Refractory Classic Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-07-18", "completion_date": "2026-07-01", "has_results": true, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-05-20T07:12:59.058Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150329" }, { "nct_id": "NCT05409066", "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma (FL)" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 549, "start_date": "2022-09-20", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-05-09T23:54:25.429Z", "location_count": 31, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05409066" }, { "nct_id": "NCT03600441", "title": "Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Abexinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xynomic Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2018-08-27", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-04-10", "last_synced_at": "2026-07-30T05:36:58.182Z", "location_count": 9, "location_summary": "Park Ridge, Illinois • Louisville, Kentucky • Lake Success, New York + 5 more", "locations": [ { "city": "Park Ridge", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600441" }, { "nct_id": "NCT04072458", "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Cutaneous T-cell Lymphoma (CTCL)", "DLBCL", "Follicular Lymphoma", "Hodgkin Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Peripheral T-cell Lymphoma (PTCL)", "Small Lymphocytic Lymphoma (SLL)", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "L-Bcl-2 antisense oligonucleotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bio-Path Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-11-05", "completion_date": "2025-04", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-16T01:55:47.738Z", "location_count": 5, "location_summary": "Augusta, Georgia • Valhalla, New York • Nashville, Tennessee + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Valhalla", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072458" }, { "nct_id": "NCT03015896", "title": "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "David Bond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-02-14", "completion_date": "2026-08-28", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-16T00:00:14.711Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Columbus, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015896" }, { "nct_id": "NCT07098364", "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High-Grade B-Cell Lymphoma", "Recurrent Indolent B-Cell Non-Hodgkin Lymphoma", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High-Grade B-Cell Lymphoma", "Refractory Indolent B-Cell Non-Hodgkin Lymphoma", "Refractory Primary Mediastinal Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Lymphodepletion Therapy", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Vevoctadekin", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2025-12-27", "completion_date": "2043-10-04", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-15T09:32:08.786Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07098364" } ] }